A Survey of Adults and Children With Allergic Rhinoconjunctivitis (MK-7243-021)

Completed

• Conditions: Allergic Rhinoconjunctivitis

• Registration Number: NCT01535118
• Lead Sponsor: ALK-Abelló A/S

Brief Summary

This study will gather information on allergic rhinoconjunctivitis from surveys completed by adults and children.

Detailed Description

Not available

Study Timeline

• Study Start: 2012-01
• Study First Submitted: 2012-02-14
• Study First Submitted QC: 2012-02-14
• Study First Posted: 2012-02-17
• Primary Completion: 2012-05
• Study Completion: 2012-05
• Results First Submitted: 2013-12-09
• Results First Submitted QC: 2013-12-09
• Results First Posted: 2014-01-27
• Status Verified: 2017-01
• Last Update Submitted: 2017-01-18
• Last Update Posted: 2017-03-03

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 2765

Inclusion Criteria

• Diagnosed with hay fever, rhinitis or nasal and/or eye allergies and display symptoms of sneezing, itching, watery eyes, nasal congestion, or other nasal or eye allergy symptoms over the past 12 months OR take any medication for their hay fever, rhinitis, nasal or eye allergies
• 5 years of age or older
• Have a telephone

Exclusion Criteria

• If less than 18 years old and there is no adult available that is knowledgeable about the participant's health

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Percentage of Participants Who Received Immunotherapy to Treat ARC	Within 12 months prior to survey	Participants who had ever received immunotherapy for ARC were asked about the type of immunotherapy - subcutaneous or sublingual - received. The percentage of participants who received immunotherapy to treat ARC was calculated.
Percentage of Participants Who Used Medication to Treat ARC in the Past 12 Months	Within 12 months prior to survey	Participants were asked about prescription and over-the-counter medication use for ARC. The percentages of participants who used prescription and/or over-the-counter medication to treat ARC in the past 12 months were calculated.
Percentage of Participants Who Experienced Daily Symptoms Due to Allergic Rhinoconjunctivitis (ARC)	Within 12 months prior to survey	Participants were asked about the frequency and severity of ARC symptoms when allergies were at their worst. The percentages of participants who experienced different symptoms of ARC on a daily basis when allergies were at their worst were calculated.
Percentage of Participants Who Experienced Work or School Absence Due to ARC in the Past 12 Months	Within 12 months prior to survey	Participants were asked about the impact of ARC on loss of work and school time. The percentage of participants who experienced work or school absence due to ARC in the prior 12 months was calculated.
Percentage of Participants Who Received Allergy Shots and Required Supplemental Prescription Allergy Medication	Within 12 months prior to survey	Participants who received subcutaneous immunotherapy (allergy shots) were asked about prescription and over-the-counter medication use. The percentage of participants who received allergy shots to treat ARC, had not taken over-the-counter allergy medication and required supplemental prescription allergy medication for ARC was calculated.

Secondary Outcome Measures

Name	Time	Method
Percentage of Participants Who Received Allergy Shots and Had a Co-morbid Condition of Asthma	Within 12 months prior to survey	Participants were asked about co-morbid health conditions. The percentage of participants who had received allergy shots to treat ARC and had asthma was calculated.